drugset / Trial / NCT05857267

Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety

NCT05857267

Phase 4 Completed 84 enrolled Laboratorios Poen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this study is to evaluate the tolerability of the new formulation of Dorzolamide+Timolol preservative free developed in OSD Aptar Pharma multidose system in comparison with Dorzolamide +Timolol BAK preserved ophthalmic formulation.

Timeline

Start
2023-03-07
Primary completion
2024-11-04
Completion
2024-11-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Dorzolamide Small molecule 2 %
Subject Timolol Other / unclassified 0.5 %